Current report 38/2021 – Receipt of a notification regarding a change in the total number of votes in the Company
Date prepared: 09/10/2021
Abbreviated name of the issuer: CELON PHARMA S.A.
Subject: Receipt of a notification regarding a change in the total number of votes in the Company
Legal basis: Article 70 point 1 of the Act on Public Offering – acquisition or disposal of a significant block of shares
Content of the report:
The Management Board of Celon Pharma S.A. informs that it has received the following notification from Mr. Maciej Wieczorek on a change in the total number of votes in the Company:
"Acting in accordance with Article 69 (1)(2) and Article 69 (2)(2) of the Act of July 29, 2005 on Public Offering, Conditions Governing the Introduction of Financial Instruments to Organized Trading and Public Companies ("Act on Public Offering"), I hereby wish to notify on my own behalf and on behalf of Glatton Sp. z .o.o., in which I hold 100% of shares, of a change in the total number of votes in Celon Pharma S.A. (the "Company").
1. The date and type of event giving rise to the change in shareholding to which the notification relates:
The event giving rise to a change in the total number of votes in the Company was the registration of an increase in the Company's share capital through the issue of D-series shares on September 9, 2021.
2. The number of shares held prior to the change and their percentage share in the Company's share capital as well as the number of votes from those shares and their percentage share in the total number of votes:
Prior to the registration of the Company's share capital increase, indirectly through Glatton Sp. z o.o., I held 30,003,531 shares in the Company, constituting 66.67% of its share capital, and I was indirectly entitled to 45,003,531 votes at the Company's General Meeting, which constituted 75.01% of the total number of votes, including: 15,000,000 registered privileged shares constituting 33.33% of the Company's share capital and entitling the shareholder to 30,000,000 votes at the Company's General Meeting, which constituted 50% of the total number of votes, and 15,003,531 ordinary bearer shares constituting 33.34% of the Company's share capital and entitling the shareholder to 15,003,531 votes at the Company's General Meeting, which constituted 25.01% of the total number of votes.
3. The number of shares currently held and their percentage share in the Company's share capital as well as the number of votes from those shares and their percentage share in the total number of votes:
After the registration of the Company's share capital increase, indirectly through Glatton Sp. z o.o., I held 30,003,531 shares in the Company, constituting 58.83% of its share capital, and I am indirectly entitled to 45,003,531 votes at the Company's General Meeting, which constituted 68.19% of the total number of votes, including: 15,000,000 registered privileged shares constituting 29.41% of the Company's share capital and entitling the shareholder to 30,000,000 votes at the Company's General Meeting, which constituted 45.45% of the total number of votes, and 15,003,531 ordinary bearer shares constituting 29.42% of the Company's share capital and entitling the shareholder to 15,003,531 votes at the Company's General Meeting, which constituted 22.73% of the total number of votes.
I did not and do not directly hold shares in the Company.
4. Subsidiaries of the notifying shareholder holding shares in the Company:
I do not have any subsidiaries other than Glatton Sp. z o.o. that would hold shares in the Company.
5. Persons referred to in Article 87 (1)(3) (c) of the Act on Public Offering:
Not applicable
6. The number of votes from shares, calculated in the manner specified in Article 69b (2) of the Act on Public Offering, which the shareholder is authorized or obliged to acquire as a holder of financial instruments referred to in Article 69b (1)(1) of the Act on Public Offering, and financial instruments referred to in Article 69b (1)(2) of the Act on Public Offering, which are not executed exclusively through cash settlement, the type or name of those financial instruments, their expiration date and the date or deadline when the purchase of shares will or can take place:
Not applicable.
7. The number of votes from shares, calculated in the manner specified in Article 69b (3) of the Act on Public Offering, to which the financial instruments referred to in Article 69b (1)(2) of the Act on Public Offering relate directly or indirectly, the type or name of those financial instruments and the expiration date of those financial instruments:
Not applicable.
8. The total number of votes indicated pursuant to points 3, 6 and 7 and its percentage share in the total number of votes:
45,003,531 votes at the Company's General Meeting, constituting 68.19% of the total number of votes."